CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / Abbvie INC. (ABBV) / etentamig
Forward catalyst · ABBV

etentamig

Sponsor Abbvie INC. · listed as ABBV

READOUT Phase 3 Confidence: medium Source: clinicaltrials

etentamig is a clinical-stage drug asset sponsored by Abbvie INC., listed as ABBV. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2027 (month precision, medium confidence), tied to trial NCT06158841. The asset is in Phase 3 and currently active not recruiting, studied in Multiple Myeloma. It appears across 4 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-12-31
As disclosedDec 2027
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06158841
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorAbbVie
Listed asABBV
Condition(s)Multiple Myeloma
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More ABBV catalysts

Related catalysts and sponsor